7,00 €
1,36 % gestern
L&S, 3. Oktober, 22:54 Uhr
ISIN
US98422E1038
Symbol
XERS
Berichte

Xeris Biopharma Holdings Aktie News

Neutral
Business Wire
etwa 14 Stunden alt
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2025, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 382,975 shares ...
Positiv
Seeking Alpha
29 Tage alt
Xeris Biopharma delivered record Q2 revenue, driven by Recorlev's rapid adoption, and is on track to achieve breakeven in Q3. Recorlev is the primary growth engine, while Gvoke provides steady diversification; Keveyis' contribution is expected to continue declining. XP-8121, a once-weekly levothyroxine, offers significant long-term upside but introduces future funding risks for Phase 3 trials.
Neutral
Business Wire
etwa ein Monat alt
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced the U.S Patent and Trademark Office has issued patent number 12,377,096 to the Company for Recorlev® (levoketoconazole) and that this patent is now...
Neutral
Seeking Alpha
etwa 2 Monate alt
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications John P. Shannon - CEO & Director Steven M.
Positiv
The Motley Fool
etwa 2 Monate alt
Xeris (XERS) Q2 Revenue Jumps 49%
Neutral
Business Wire
etwa 2 Monate alt
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter ended June 30, 2025, and updated its fiscal 2025 guidance. “Total revenue in the second quarter increased ...
Neutral
Business Wire
2 Monate alt
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2025 financial results before the open of the U.S. financial markets on Thursday, August 7, 2025. ...
Positiv
Seeking Alpha
4 Monate alt
Compared to other biotech companies, Xeris Biopharma Holdings Inc. is a company that has successfully launched products that are already generating revenue. As the company's revenue is expected to grow significantly by 2030, the stock price may rise accordingly. Moreover, XP-8121 may serve as a catalyst for higher stock valuation.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen